Hikma v. Amarin: Pleading “Active Steps” for §271(b) Inducement—Affirmative Encouragement, Not Possible Reader Inferences

1. Introduction

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (608 U. S. ___ (2026)) sits at the intersection of Hatch-Waxman generic-drug approval, “skinny label” carve-outs, and patent-law inducement liability under 35 U. S. C. §271(b).

The dispute arose after Amarin obtained method-of-use patents covering a cardiovascular-risk-reduction use of its brand drug Vascepa (the “CV indication”), while Hikma sought to market a generic version using a section viii statement and a skinny label limited to the non-patented use for severe hypertriglyceridemia (the “SH indication”).

Amarin alleged that, notwithstanding Hikma’s carve-out label, Hikma actively induced infringement of the CV method through the “totality” of its communications (label/leaflet, website, and investor-facing press releases). The District Court dismissed under Rule 12(b)(6), but the Federal Circuit reinstated the case as “plausible” because a physician could read those statements as encouragement to infringe.

The Supreme Court unanimously reversed, holding that the pleadings must plausibly show that the defendant actively encouraged infringement through affirmative steps—not merely that third parties could plausibly interpret statements as infringing instructions.

2. Summary of the Opinion

The Court held that Amarin failed to state a claim for inducement under §271(b) because its complaint did not plausibly allege Hikma took “active steps” to encourage infringement. The key pleading inquiry is the defendant’s affirmative encouragement, not the possibility that doctors could read materials as infringing instructions.

Applying Twombly/Iqbal, the Court found Amarin’s allegations either (i) had an “obvious alternative explanation” (legal compliance or industry practice), (ii) relied on non-action/omissions, or (iii) were too vague and dependent on speculation and an attenuated chain of events (especially the press-release sales figures).

3. Analysis

3.1. Precedents Cited

  • Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, 566 U. S. 399 (2012)
    Role in the opinion: Provides the Hatch-Waxman framework for ANDAs, paragraph IV certifications, section viii carve-outs, and “skinny labels,” and underscores that generics are “biologically equivalent” to the brand. The Court uses Caraco to contextualize why substitution is common and why Congress created pathways to market generics without infringing patented uses—while still leaving room for inducement liability when a generic affirmatively promotes infringement.
  • Eli Lilly & Co. v. Medtronic, Inc., 496 U. S. 661 (1990)
    Role in the opinion: Cited to explain Hatch-Waxman’s purpose of reducing duplicative testing and accelerating generic entry. This policy backdrop informs the Court’s caution against expanding inducement theories that would make ordinary, compliance-driven conduct actionable.
  • Inwood Laboratories, Inc. v. Ives Laboratories, Inc., 456 U. S. 844 (1982)
    Role in the opinion: Used for two points: (i) medical substitution is routine, including substitution that may incidentally lead to infringing uses; and (ii) it is “normal industry practice” to truthfully describe a generic as “equivalent” to the brand. The Court relies on Inwood to reject the idea that calling a product “generic Vascepa” or an equivalent is, without more, an inducement “active step.”
  • Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd., 545 U. S. 913 (2005)
    Role in the opinion: Grokster supplies the core “active steps” requirement: inducement requires “purposeful, culpable expression and conduct,” not “ordinary acts incident to product distribution.” The Court also draws a critical line between statements “designed to stimulate” infringement and statements that merely “could” do so. Grokster becomes the Court’s lens for distinguishing affirmative promotion from passive foreseeability.
  • Limelight Networks, Inc. v. Akamai Technologies, Inc., 572 U. S. 915 (2014)
    Role in the opinion: Cited for the first element of inducement: there must be direct infringement by a third party. While not contested here, it anchors the Court’s statement of the inducement framework.
  • Global-Tech Appliances, Inc. v. SEB S. A., 563 U. S. 754 (2011)
    Role in the opinion: Cited for two propositions: (i) the inducer must know the induced acts constitute infringement, and (ii) inducement requires “affirmative” steps “to bring about the desired result.” The Court uses Global-Tech to refocus the pleading inquiry on the defendant’s purposeful conduct, not on third-party interpretation.
  • Bell Atlantic Corp. v. Twombly, 550 U. S. 544 (2007) and Ashcroft v. Iqbal, 556 U. S. 662 (2009)
    Role in the opinion: Provide the plausibility framework at the motion-to-dismiss stage. The Court emphasizes “obvious alternative explanation[s]” (Twombly) and the need for more than a “sheer possibility” (Iqbal) to plead “active steps” under §271(b).
  • Twitter, Inc. v. Taamneh, 598 U. S. 471 (2023)
    Role in the opinion: Imported to clarify that liability—here inducement—cannot rest on “mere omissions, inactions, or nonfeasance.” The Court deploys Taamneh to reject theories premised on Hikma’s failure to highlight SH-only approval or failure to include limiting language beyond what the skinny label did.
  • PLIVA, Inc. v. Mensing, 564 U. S. 604 (2011)
    Role in the opinion: Supports the “duty of sameness”: generic labeling must match the brand label except for permitted differences. This becomes central to the Court’s “alternative explanation” analysis: retention of certain study information and omission of the CV limitation were plausibly explained by statutory/regulatory compliance, not inducement.
  • Takeda Pharmaceuticals U. S. A., Inc. v. West-Ward Pharmaceutical Corp., 785 F. 3d 625 (CA Fed. 2015)
    Role in the opinion: Quoted for the principle that inducement cannot be based on “vague” language combined with speculation about how others may act. The Court uses Takeda to reject Amarin’s chain-of-inference approach as insufficiently tethered to affirmative encouragement.
  • GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F. 4th 1320 (CA Fed. 2021)
    Role in the opinion: Cited to explain what an “AB” rating signifies—therapeutic equivalence only “under the conditions specified in the generic’s label.” That meaning undercuts any inference that an AB rating is designed to promote patented off-label use.
  • National Rifle Association of America v. Vullo, 602 U. S. 175 (2024)
    Role in the opinion: The Court rejects Amarin’s attempt to import Vullo’s coercion standard (whether conduct “could be reasonably understood” as a threat) into patent inducement, warning that such a move would dilute §271(b)’s requirement of “activ[e] induce[ment].”
  • Cox Communications, Inc. v. Sony Music Entertainment, 607 U. S. ___ (2026)
    Role in the opinion: Reinforces the theme that mere knowledge of infringement potential is insufficient and that the inquiry looks for “express promotion” or marketing-type encouragement, aligning inducement’s boundary with “regular commerce.”

3.2. Legal Reasoning

The Court’s reasoning proceeds in three moves that, together, create the opinion’s main doctrinal clarification.

A. Re-centering the “active steps” inquiry on the defendant’s conduct

The Federal Circuit’s approach asked whether it was plausible that a physician could read the challenged materials “as an instruction or encouragement” to infringe. The Supreme Court rejects that framing as insufficiently faithful to §271(b). The statutory phrase “actively induces” demands a focus on whether the defendant’s communications and conduct plausibly constitute affirmative encouragement—i.e., purposeful steps “to bring about the desired result” of infringement (Global-Tech; Grokster).

This is not a requirement of “magic words” or necessarily “express” incitement. The Court acknowledges implicit inducement is possible (as in Grokster’s “OpenNap” example), but insists the encouragement must still be clear, affirmative, and designed to stimulate infringement—not a speculative inference layered atop lawful distribution.

B. Applying Twombly/Iqbal to filter out lawful “alternative explanations”

A central feature of the Court’s Rule 12(b)(6) analysis is that multiple statements Amarin relied upon were readily explained by legal compliance and industry norms:

  • Label content and study references: generic labels must largely mirror the brand label (the “duty of sameness”), so similarity is not plausibly an inducement step.
  • “Generic equivalent” / “generic Vascepa” descriptions: describing therapeutic equivalence is normal and lawful industry practice, and the Court refuses to transform such baseline communications into inducement building blocks.

In other words, where the pleaded facts fit comfortably within mandated regulatory behavior or standard generic-market practice, the complaint does not “nudge” the claim into plausibility absent additional, more pointed allegations.

C. Excluding omissions and attenuated chains of inference from “active steps”

The Court expressly bars reliance on omissions or nonfeasance (Twitter, Inc. v. Taamneh). Thus, Amarin could not plead inducement by alleging Hikma failed to include additional limiting language, or failed to emphasize in press releases that approval was SH-only.

The Court then treats the remaining statements (leaflet warnings/disclaimer, website category/AB rating, press-release sales figures) as too vague and too dependent on a multi-step speculative narrative about who would read the materials, how they would interpret them, and how that would translate into infringing prescriptions. This is where the Court most clearly operationalizes its rule: §271(b) is not satisfied by a “plausible chain of events” in which neutral statements could indirectly lead to infringement; it requires plausible allegations that the defendant’s speech or conduct was affirmatively designed to bring about infringement.

3.3. Impact

A. Immediate procedural impact: a higher bar at the pleading stage for skinny-label inducement

The opinion strengthens defendants’ ability to obtain Rule 12(b)(6) dismissal where inducement claims rest on: (i) regulatory-mandated labeling similarity, (ii) general equivalence statements, (iii) omissions, or (iv) ambiguous, investor- or public-facing communications not targeted as prescriber instructions.

B. Substantive impact: narrowing inducement theories based on “how doctors might read it”

The Court expressly rejects a “trend” that focuses on whether statements could be read as infringing instructions. Future cases are likely to scrutinize whether the alleged materials function as affirmative promotion of the patented method (e.g., targeted marketing to prescribers, training, sales scripts, detail aids, formularies communications, or other conduct plausibly designed to stimulate the infringing use).

C. Regulatory/policy impact: reducing tension with Hatch-Waxman’s carve-out design

By treating compliance with the “duty of sameness” and routine generic-equivalence messaging as “obvious alternative explanation[s],” the Court lowers the risk that section viii carve-outs become practically unusable due to inducement exposure grounded in the very communications that accompany lawful generic entry.

D. Litigation strategy impact: what patentees will need to allege (and defendants will try to negate)

Patentees bringing §271(b) claims involving carved-out labels will likely need to plead more concrete, affirmative encouragement—communications directed to prescribers/pharmacists that connect the generic product to the patented method-of-use population or regimen in a way that looks like promotion rather than compliance or neutral description. Defendants, conversely, will emphasize alternative explanations rooted in FDA requirements, common industry terminology, and audience/intent (investor relations vs. prescriber marketing).

4. Complex Concepts Simplified

  • Method-of-use patent: A patent not on the molecule itself, but on using the drug for a particular treatment or patient population (here, reducing cardiovascular risk in certain patients).
  • NDA vs. ANDA: A brand files an NDA with full safety/efficacy data; a generic files an ANDA relying on the brand’s data to show bioequivalence.
  • Paragraph IV certification: The generic asserts a listed patent is invalid or not infringed, triggering litigation.
  • Section viii statement & skinny label: The generic seeks approval only for non-patented uses and “carves out” patented indications from its label.
  • Orange Book: FDA’s listing of drug products and associated patents; it structures how ANDAs address patents.
  • AB rating: A therapeutic equivalence code indicating substitutability when used as labeled—not an instruction to use the drug for every use of the brand regardless of label limits.
  • Induced infringement (§271(b)): You can be liable not only for directly infringing, but for actively encouraging someone else to infringe—requiring affirmative steps, not mere knowledge or passive distribution.
  • Twombly/Iqbal plausibility: A complaint must allege enough concrete facts to make liability a reasonable inference, and must overcome obvious lawful explanations for the defendant’s conduct.
  • Omissions/nonfeasance: Failing to say something (or failing to do more) generally cannot substitute for the affirmative encouragement required for inducement.

5. Conclusion

Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. clarifies that, for §271(b) inducement—particularly in the skinny-label context—the pleading burden is not satisfied by alleging that prescribers could plausibly interpret scattered, largely lawful communications as encouraging infringement. The complaint must plausibly allege that the defendant itself took affirmative, clear steps designed to encourage the patented use.

The decision realigns inducement doctrine with Grokster’s emphasis on purposeful promotion, imports Taamneh’s insistence on affirmative assistance (not omissions), and uses Twombly/Iqbal to screen out claims built from legal compliance, industry norms, and speculative inference chains—significantly shaping how future Hatch-Waxman inducement disputes will be pleaded and litigated.